An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Noske, Aurelia ^a,b   Schwabe, Michael ^a   Weichert, Wilko ^c   Darb Esfahani, Silvia ^a   Buckendahl, Ann Christin ^a   Sehouli, Jalid ^a   Braicu, Elena I ^a   Budczies, Jan ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

COX 2; CRM1; EGFR; Ovarian cancer; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EXPORTIN 1; LEPTOMYCIN B; CANCER ANTIBODY; CELL RECEPTOR; EGFR PROTEIN, HUMAN; EXPORTIN 1 PROTEIN; KARYOPHERIN; MONOCLONAL ANTIBODY; PTGS2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; UNSATURATED FATTY ACID;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; TARGET CELL; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CARCINOMA; CHEMISTRY; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RABBIT; SINGLE BLIND PROCEDURE; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; CARCINOMA; CELL LINE, TUMOR; COHORT STUDIES; CYCLOOXYGENASE 2; FATTY ACIDS, UNSATURATED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KAPLAN-MEIER ESTIMATE; KARYOPHERINS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SINGLE-BLIND METHOD; TUMOR MARKERS, BIOLOGICAL;

EID: 79960554120     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-294     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010, 568938.
3. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 2009, 101(1):149-159. 10.1038/sj.bjc.6605112, 2713689, 19513073.
4. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, Mirlacher M, Sauter G, Mihatsch MJ, Singer G. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006, 19(4):607-610. 10.1038/modpathol.3800575, 16554736.
5. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006, 84(8):671-681. 10.1007/s00109-006-0054-4, 16607561.
6. Dimova I, Zaharieva B, Raitcheva S, Dimitrov R, Doganov N, Toncheva D. Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors. Int J Gynecol Cancer 2006, 16(1):145-151. 10.1111/j.1525-1438.2006.00286.x, 16445625.
7. Vermeij J, Teugels E, Bourgain C, Xiangming J, in 't Veld P, Ghislain V, Neyns B, De Greve J. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008, 8:3. 10.1186/1471-2407-8-3, 2266762, 18182111.
8. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004, 14(6):1086-1096. 10.1111/j.1048-891X.2004.14606.x, 15571614.
9. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997, 90(6):1041-1050. 10.1016/S0092-8674(00)80370-0, 9323132.
10. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18(6):1660-1672. 10.1093/emboj/18.6.1660, 1171253, 10075936.
11. Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun 2005, 332(1):167-173. 10.1016/j.bbrc.2005.04.109, 15896313.
12. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, Bartholomeusz G, Wang SC, Hung MC. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005, 25(24):11005-11018. 10.1128/MCB.25.24.11005-11018.2005, 1316946, 16314522.
13. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006, 98(6):1570-1583. 10.1002/jcb.20876, 16552725.
14. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008, 112(8):1733-1743. 10.1002/cncr.23354, 18306389.
15. Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W. ["IMO"--intraoperative mapping of ovarian cancer]. Zentralbl Gynakol 2003, 125(3-4):129-135.
16. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. Gynecol Oncol 1998, 70(1):2-12. 10.1006/gyno.1998.5051, 9698465.
17. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, Sehouli J, Dietel M, Denkert C. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 2008, 20(6):1409-1417.
18. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(6):918-927. 10.1200/JCO.2009.25.2890, 20100958.
19. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160(3):893-903. 10.1016/S0002-9440(10)64912-7, 1867167, 11891188.
20. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005, 11(24 Pt 1):8637-8643.
21. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008, 99(2):341-349. 10.1038/sj.bjc.6604471, 2480978, 18628764.
22. Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 2008, 27(3):380-389. 10.1097/PGP.0b013e31815d060d, 18580315.
23. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007, 67(13):6121-6129. 10.1158/0008-5472.CAN-07-0141, 17616668.
24. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23(2):254-266. 10.1200/JCO.2005.09.112, 15637389.
25. Jeong KJ, Park SY, Seo JH, Lee KB, Choi WS, Han JW, Kang JK, Park CG, Kim YK, Lee HY. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 2008, 40(6):607-616. 10.3858/emm.2008.40.6.607, 2679339, 19116446.
26. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446(7137):765-770. 10.1038/nature05760, 17429393.
27. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003, 98(7):1423-1429. 10.1002/cncr.11650, 14508829.